Abstract Objectives: The aim of this study was to assess the concurrent validity between the identification of suboptimal treatment based on clinical information and computer generated indicators. Indicators that are associated with sub-optimal treatment in one of the four steps of asthma management were assessed. Design: The ability of each indicator to identify patients with sub-optimal asthma treatment from computerised general practitioner (GP) prescription records was assessed by comparing them with the results of an individual patient assessment using clinical data. Setting: Chronic asthma patients (n=146) registered with 16 Dutch GPs. Main measures: The sensitivity and positive predictive value (PPV) of each performance indicator was determined.
Introduction
Quality assessment and improvement is receiving attention world wide. Information on health-care quality is being demanded by policy makers, health-care professionals and the general public alike [1, 2, 3, 4, 5, 6, 7] . With the majority of doctor-patient encounters in general practice resulting in a prescription for drug treatment, the quality of prescribing in general practice is an important issue [8] . Prescribing indicators for general practice have been used in several countries, for example, in the US, UK, Australia and Netherlands [7] . They are likely to keep a central role in programs to optimise care and are used for a range of purposes. The most important are (1) identification of patients receiving sub-optimal care, (2) monitoring of change or assessing the outcome of interventions and (3) identification of poor performers for purposes of postgraduate education or accountability and regulationmeaningful indicators from accurate data is a challenge [7] . This is especially the case for conditions that require a complex treatment regime according to severity, such as asthma.
Asthma is a chronic condition affecting more than 8% of adults in Western Europe. It is commonly treated in general practice [10] . Since the early 1990s, international asthma treatment guidelines have been available, which provide clear, well-accepted recommendations regarding optimal asthma management. Asthma is a variable disease, where the severity is determined by symptoms and lung function. The international consensus distinguishes four different levels of severity, each demanding a different treatment with medicines, i.e. optimal asthma pharmacotherapy is a step-wise process with treatment differing for each of the four asthma severity classes [11, 12, 13] .
Various indicators have been developed for assessing the quality of asthma treatment in general practice, based on the recommendations in the international guidelines [14, 15, 16, 17, 18, 19, 20, 21] . Most indicators are derived from easily accessible prescription data. Commonly used asthma indicators focus on the proportion of patients prescribed a particular medication, such as inhaled corticosteroids or short-acting b-agonists, without taking into account differences in asthma severity [16, 17, 22 ]. An international collaboration developed a set of five asthma-prescribing indicators, attempting to differentiate among asthma severity classes using drug-based proxies. These indicators were used to evaluate an international intervention for improving asthma care in general practice [18, 23, 24] . The face and content validity of these indicators was considered good [23, 24] . Face validity indicates that the indicator appears to measure what it purports to and content validity means that the indicator is considered to be relevant. However, later work showed little correlation between indicators designed to target the same suboptimal treatment pattern [19] , suggesting that face and content validity alone may not be adequate for determining indicator validity. Concurrent validity, that is, comparison with a reference measure, is needed to fully determine the validity of performance indicators. The aim of this study was to assess the concurrent validity between the identification of sub-optimal treatment based on clinical information and computer generated indicators.
Materials and methods

Study population and recruitment procedure
The Registration Network Groningen (RNG) is a general practice database in the northern Netherlands. At the time of the study, the RNG included 30,486 patients registered with 16 general practitioners (GPs). Participating GPs use the database in clinical practice in place of paper medical records. Due to this, all prescriptions can be linked to the indication asthma, as diagnosed by the GP.
All patients aged 18-49 years with an asthma medication (Anatomical Therapeutic Chemical classification-ATC [25] group R03) or an asthma contact (International Classification of Primary Care-ICPC [26] code R96) during 1997 were selected from this database. Patients who received asthma medications for nonasthma indications were excluded, as well as patients who were no longer registered with an RNG doctor. Data from 1997 were used for recruitment to ensure that patients had chronic asthma in the study period. Eligible patients were invited to an individual study appointment by their GP, who unlocked the ''key'' that is used in the database to safeguard anonymity. A reminder letter was sent to non-respondents within 3 months of the initial invitation. Anonymous data for eligible non-responders were used for comparison regarding age, sex and asthma medication use. The local medical ethics committee approved the study, and informed consent was obtained from each participant.
Validation process
We validated indicators that targeted sub-optimal treatment patterns related to four steps included in the 1997 National Institutes of Health (NIH guidelines) [12] .
Step 1.
Under-treatment of short-acting inhaled b-agonists for all asthma patients Step 2.
Under-treatment of inhaled corticosteroids for mild, moderate or severe persistent asthma Step 3.
Inadequate dose of inhaled corticosteroids for moderate or severe persistent asthma Step 4.
Under-treatment of inhaled long-acting b-agonists for severe persistent asthma Every patient was classified as being sub-optimally treated within every severity level of asthma in two ways: (1) using the computer-based prescribing indicators (the ''indicators'') and (2) using information on currently used medication in relation to symptoms and lung function assessed in a study appointment (the ''individual patient assessment''). The latter classification was used as the reference value for the validation, i.e. the validation process checked to what extent the identification of sub-optimal treatment based on clinical information can be reproduced by computer generated indicators.
Indicators
The indicators validated in this study have been previously developed and used internationally for assessing the quality of prescribing for chronic adult asthma [18, 20, 24] . Detailed information on the development and use of the indicators has been published elsewhere [19] . In this study, indicators were calculated using data from the RNG database from 1999-2000. For each participating asthma patient, prescription data for the 12-month period prior to the study appointment were obtained retrospectively from the GP database. The indicators, based on the sub-optimal treatment patterns related to four steps included in the 1997 National Institutes of Health (NIH guidelines) [12] were calculated as follows.
Step 1 indicator.
The patient is not prescribed an inhaled short-acting b-agonist during the 1-year period prior to the study appointment Step 2A indicator.
The patient is not prescribed an inhaled corticosteroid during a 1-year period prior to the study appointment Step 2B indicator.
The patient is not prescribed an antiinflammatory agent (either corticosteroid or cromoglycate), but is prescribed an amount of inhaled short-acting b-agonist for daily use over a 1-year period prior to the study appointment
Step 3 indicator.
The patient is prescribed a low-dose inhaled corticosteroid ( £ 400 lg budesonide or equivalent daily, Table 1 ) in combination with an inhaled short-acting b-agonist more than once daily over a 1-year period prior to the study appointment Step 4 indicator.
The patient is prescribed a high-dose inhaled corticosteroid (>600 lg budesonide or equivalent, Table 1) , and an inhaled shortacting b-agonist at least twice daily over a 1-year period prior to the study appointment, but no long-acting b-agonist
The step-2B, step-3 and step-4 indicators incorporate the average daily amount of short-acting b-agonist over a 1-year period per patient. This is used in these types of indicators as a proxy for asthma severity, assuming that higher b-agonist use is associated with more severe asthma.
Individual patient assessment
The information needed for the reference measure on sub-optimal treatment patterns was collected in an individual study appointment. Each participating patient attended a single study appointment (May 2000-December 2000) with a trained research assistant. During this appointment, a questionnaire on symptoms and medication was completed. The questions referred to symptoms of asthma, such as dyspnoea and night symptoms, during the previous week and to drug use in the previous week, asking for the name of the drug and the number of doses used per day for every drug. Patients were asked to bring all current asthma medications to the study appointment and were asked about having spare bronchodilator inhalers, which may ÔdistortÕ prescription patterns, as seen in computerised databases. Each patientÕs forced expiratory volume at 1 s (FEV 1 ) was determined according to the standards of the American Thoracic Society, using a Microlab 3300 spirometer (Micro Medical Ltd., Rochester, Kent UK). For each participant, the best of three readings was used. Each patientÕs treatment regime was then classified as being either optimal or sub-optimal, taking into account severity and current medication, according to the explicit criteria specified in the NIH guideline (Table 1) . For example, a patient with symptoms more than twice a week, but not daily, or exacerbations that may affect activity or night time symptoms more than twice a month, but not weekly, or a suboptimal, but ‡80% predicted FEV 1 , was classified as a class-2 patient. According to the NIH instructions, the presence of at least one of the features of severity is sufficient to place a patient in that severity class. An individual was assigned the most severe class in which a feature occurred.
Sample size
We defined that a valid indicator would require both a sensitivity and positive predictive value (PPV) of at least 0.7 for use in quality assessment. With a 95% confidence interval of 0.1, we calculated that at least 84 asthma patients would be needed to validate each indicator [27] . The RNG database included 369 patients meeting our inclusion criteria, and we decided to invite all eligible patients to participate in the study to ensure that our sample size requirements were met.
Analysis
Since each indicator can be viewed as a type of diagnostic test that identifies sub-optimal treatment, we assessed indicator validity in terms of sensitivity and PPV. These were calculated according to Altman [28] . The sensitivity of an indicator denotes the proportion of cases of sub-optimal treatment found in the individual assessment method, which is also identified by the indicator. The PPV is the proportion of cases identified by the indicator that is confirmed in the individual assessment.
Three of the indicators (step 2B, step 3 and step 4) incorporated levels of daily short-acting b-agonist use as a proxy for asthma severity. The association between short-acting b-agonist use and asthma severity was explored using rank correlation (KendallÕs tau). A perfect correlation yields a KendallÕs tau of 1, while a KendallÕs tau of 0 indicates no relationship. In order to assess if the cut-off levels used in each indicator could distinguish among the 
Results
Of the 369 eligible patients identified from the database, 146 were willing to participate in the study. Patient characteristics and medication use are shown in Table 2 . Current medication determined at the study appointment was higher than that obtained from the prescription database. Current short-acting b-agonist use was reported by 101 (69.2%), inhaled corticosteroids by 96 (65.8%), cromoglycates 8 (5.4%), long-acting b-agonists by 23 (15.8%) and ipratropium bromide by 19 (13.0%) participants. Of the patients not using a short-acting b-agonist, nine reported use of ipratropium bromide, and another five reported use of formoterol.
Non-respondent characteristics
Data from the GP database showed no difference with respect to gender between non-respondents and participating patients (58.2% and 57.8% female, respectively). Participating patients were slightly older (39.8 years versus 35.8 years, P<0.05). There were no significant differences between participating and non-responding patients in the mean volume prescribed per patient for inhaled short-acting b-agonists, inhaled corticosteroids, inhaled anticholinergics and oral salbutamol. Table 3 shows the sensitivity and PPVs for each indicator. The validity of the step-4 indicator could not be determined due to an insufficient number of patients with persistent severe asthma (severity class 4).
Validation of the indicators
The step-1 indicator had a sensitivity of 0.86, showing that prescription data correctly identified 86% of all patients without a short-acting b-agonist, as identified in the individual assessment. The PPV of 0.52 indicates that just over half of the patients identified by the indicator as not having a short-acting b-agonist prescribed during the study period actually did not have medication at the study appointment. The others did have this medication with them at the study appointment, either from earlier prescriptions or from prescriptions by other prescribers.
The step-2A indicator identified 74% of patients who were not prescribed an inhaled corticosteroid and who, according to their severity, should be prescribed this drug group. However, of all patients found by the indicator without an inhaled corticosteroid, less than half (PPV=0.46) were confirmed by individual assessment. The step-2B indicator had a slightly lower sensitivity than the step-2A indicator, despite targeting the same sub-optimal treatment pattern. The majority (71%) of patients identified by this indicator as in need of an inhaled corticosteroid were confirmed upon the individual assessment. The remaining 29%, upon individual assessment, were either currently using an anti-inflammatory agent or were not high users of their short-acting b-agonist or, according to their severity classification, did not need an anti-inflammatory agent.
The step-3 indicator was the poorest performing indicator. This indicator was designed to detect patients with severity class 3 or higher who were prescribed a sub-optimal inhaled corticosteroid dose. However, it detected only 7% of the patients found upon individual assessment to have an inadequate corticosteroid dose. Furthermore, just 20% of the patients identified by the indicator with a sub-optimal dose were confirmed as having a sub-optimal corticosteroid dose upon individual assessment.
Short-acting b-agonist use as a proxy for asthma severity While higher short-acting b-agonist use was significantly associated with increasing asthma severity (KendallÕs tau=0.307, P<0.001), the wide standard deviations show considerable overlap in short-acting b-agonist use among the different asthma severity levels (Table 4) . The step-2B indicator used a cut-off point for daily short-acting b-agonist use (200 lg of salbutamol daily or equivalent) to identify patients with a severity class of more than one from prescription data. As seen in Fig. 1a , this cut-off point correctly classified only 58.7% of all patients. The step-3 indicator used a cut-off point of high daily short-acting b-agonist use (400 lg salbutamol daily or equivalent) to identify patients of a severity class of more than two; however, this cut-off point correctly classified only 43.9% of patients (Fig. 1b) . Neither curve flattens considerably at any point, indicating that no optimal short-acting b-agonist levels could be identified.
Patients were asked during the study appointment about having spare bronchodilator inhalers. More than half of the patients being prescribed a short-acting b-agonist reported using multiple inhalers simultaneously (55.7%). Of these, 50.7% reported having one spare inhaler, 34.3% kept two spares and the remaining 14.9% kept between three and five extra short-acting b-agonist inhalers.
Discussion
In this study, we evaluated the concurrent validity of five performance indicators derived from computerised prescription data for assessing the treatment of asthma. Two general indicators, which looked at the total number of patients prescribed short-acting b-agonist or inhaled corticosteroids, had reasonable sensitivities, but low PPVs. The two indicators that incorporated proxies for asthma severity had much lower sensitivities and varied PPVs.
While the response rate in this study was rather low, there is no reason to believe that this would affect the outcomes of our validation study. An adequate number of patients was recruited to validate four of the five indicators. No difference was seen between participants and non-respondents with respect to gender and the use of the different asthma medications, although participating patients were slightly older. We used a general practice database for calculating the prescribing indicators. This database gives an accurate account of all treatments prescribed by a GP to patients diagnosed with asthma. In the Netherlands, asthma medications are available only on prescription, and, in general practice, patients register with a single GP. Thus, the database contains complete records regarding the asthma management of GPs. Pharmacy records or claims data without information on disease are considered less reliable in identifying patients with asthma [29] . A limitation of using a GP database is that it does not register prescriptions from specialists. In the Netherlands, patients referred to a specialist may initially receive a prescription from the specialist, but generally return to their GP for further medication supply. For chronic medication, this is expected to result in a slight underestimation of medication when looking at a GP database during a 1-year period.
A GP prescription database can never fully reflect actual use of medications. It overestimates actual use when patients do get prescriptions, but are not collecting or using the medication. However, it may underestimate actual use when patients use their medication intermittently, and, therefore, do not need a new prescription during a 1-year period. In the Netherlands, one prescription may be valid for a maximum of a 3-month supply, but for medication that is used intermittently (''as needed''), a prescription may cover a longer period. This is expected to be the case for some relief medication, such as inhaled short-acting b-agonists, but it is also known that asthma patients sometimes use their inhaled corticosteroids intermittently. This could explain the finding that the number of patients identified from the GP database on certain medications during the study period was somewhat lower than as determined during the study appointment with the patients themselves. Self-reported medication use, by patient interview, has been shown to be a reliable method of obtaining current medications [30, 31, 32] . In this study, the accuracy of self-reported medication use was further improved by having patients bring their asthma medications to the study appointment. This would include specialist-prescribed medication as well as medication prescribed prior to the study period, but still used.
A limitation of this study is that the clinical assessment of treatment quality referred to the previous week, while prescribing indicators were based on prescribing in the previous year. This may have led to an underestimation of the validity of the prescribing indicators, since asthma severity might have changed during the preceding year. However, four of the indicators (step1, step 2A, step 2B and step 3) identify sub-optimal prescribing, in particular under-treatment, for several severity steps. Sub-optimal prescribing for step 1 includes, by definition, sub-optimal prescribing for steps 2, 3 and 4. This implies that changes in severity are covered by these indicators, with the exception of the step-4 indicator, which could not be validated due to lack of data.
The sensitivity and PPVs required for validity vary depending on the purpose for which the indicator is to be used. If an indicator is being used to identify patients with potential treatment problems, then it is important that the initial screening process identifies as many patients as possible who then undergo further, more accurate testing. Thus, for this purpose, indicators should have a high sensitivity. Of the five indicators validated in this study, both step 1 and step 2A indicators could be considered valid screening indicators; though still far from ideal, no better alternatives exist. The step-1 indicator identified 86% of all patients without an inhaled short-acting b-agonist, while the step 2A indicator detected 74% of patients not prescribed an inhaled corticosteroid who should have one according to their severity classification.
If an indicator is being used to monitor changes in drug utilisation or to assess the outcome of an intervention, then one may be satisfied with identifying only a selection of the patients of interest. In this case, the PPV becomes relatively more important than the sensitivity. Thus, if one is satisfied with monitoring changes or intervention outcomes in a sub-sample of patients, the step-2B indicator could be considered valid. Although this indicator identified less than half of all patients needing an inhaled corticosteroid, more than 70% of the patients identified were confirmed as needing an inhaled corticosteroid upon the individual assessment.
One of the common uses of prescribing indicators is to assess the performance of doctors. To be considered valid for assessing performance, an indicator needs to identify as many sub-optimally treated patients as possible while being certain that the all the patients identified are actually being treated sub-optimally. That is, both the sensitivity and PPVs should be sufficiently high. Clearly, none of the indicators based on prescription data validated in this study can be considered valid for this purpose.
A major problem affecting the validity of three of the indicators studied (step 2B, step 3 and step 4) was the inadequacy of using the prescription volume of shortacting b-agonist as proxy of asthma severity. While we observed a significant relationship between short-acting b-agonist use and asthma severity class, the range of use was extremely wide, and no clear cut-off points could be found that distinguished clearly among the different severity classes. More than half of the patients reported using multiple short-acting b-agonist inhalers simultaneously. Given the role of these medications as symptom relievers, it is understandable that patients may keep spare inhalers to ensure that one is always readily available. When calculating the average amount of short-acting b-agonist use over a 1-year period, patients using multiple inhalers simultaneously could appear to be high users if they have received a high number of repeat prescriptions during the study period, while, in reality, they may be moderate or even low users.
One may question whether the low sensitivity and PPV will also be found in other asthma populations. Of course, all validation scores are determined by the underlying treatment pattern. Differences may be found, for example, when b-agonist use is more indicative of actual asthma severity than in the studied asthma population. However, this seems hardly likely, since treatment patterns in this population are much in line with that found in other countries in Europe [18] .
This study emphasises the need for more information regarding the validity of the indicators calculated from computerised prescription data currently in use for assessing treatment quality. Computerised data may be easily available, however, in many instances, they may not provide enough information to judge a doctorÕs performance. This is, in particular, the case in complex diseases, such as asthma. Face and content validity, on which validation has centred to date [33, 34, 35] , are not adequate substitutes for concurrent validity, checking if an indicator adequately describes what can be observed in actual clinical practice.
Prescribing indicators calculated from other databases than a GP database will probably have lower validity estimates than found in this study. If only prescribing data and no indication is available (as in sales data, claims data or pharmacist records), misclassification of patients occurs, undermining the possibility of a valid assessment of prescribing quality for a specific disease [29] . With the computerisation in general practice, however, the availability of GP databases and data on prescribing linked to indication increases fast in Europe.
Before an indicator is used, information on its sensitivity and PPV should be known. In the case of asthma and other complex diseases, prescribing indicators can only be used as a broad-brush approach to treatment quality when additional information on asthma severity class and actual use of asthma medications by the individual patient is lacking. This is even more of the case when no data are available that may link patients over time to prescribing behaviour or in the absence of a diagnosis. None of the commonly used asthma indicators calculated from prescription databases that were evaluated in this study can be considered a valid tool for assessing the quality of doctorsÕ performance in the management of asthma.
With the growing international interest in performance indicators, this study emphasises the importance of indicator validation and underlines that performance indicators should only be used with caution.
